

PRESS RELEASE, 1 August 2003

Perbio Science AB Interim Report January-June 2003

Healthy sales growth impacted by weak US dollar

- Net sales were SEK 1,033 (1,108) million which, as a result of the weak US dollar, was a decline of 7 percent. In dollar terms sales increased 15 percent to USD 124.2 (108.4) million
- Gross margin improved to 46.6 percent (45.9 percent)
- Profit after financial items was SEK 171 (190) million, a decline of 10 percent, but rose 11 percent in US dollars to USD 20.6 (18.6)
- Earnings per share after full dilution declined 11 percent to SEK 2.77 (3.12)
- Public offer from Fisher Scientific International Inc. to purchase for cash all
 outstanding shares and warrants granted under the 1999 program for SEK 142.50 per
 share and SEK 93.50 per warrant was made. The offer will be open until August 14

Bioresearch Division

- Sales were up 3 percent in USD
- Europe market continues to register the strongest sales development
- Operating margin was reduced to 17.4 percent (20.4 percent) mainly due to non-recurring license revenue in the first half of 2002

Cell Culture Division

- Sales were up 17 percent in USD
- BioProcess Containers (BPC) showed continued healthy growth
- Operating margin remained unchanged at 17.3 percent (17.3 percent)

Medical Device Division

- Strong growth continued, sales were up 25 percent in SEK
- Operating margin rose to 23.4 percent (21.3 percent)



"During the first six month we have been able to maintain a healthy growth. Measured in our major currency the US Dollar, the quarter was Perbio's best ever" says **CEO** Leland Foster.

Further information
Leland G Foster, CEO
phone +1 435 757 6432
procedure Wenthzel, Vice President & CFO
phone: +46 42 26 90 92 or +46 70 862 01 22

Perbio Science AB (publ) is a listed Swedish biotech company with research institutions, pharmaceutical companies and diagnostic companies as its customers. The USA accounts for the bulk of its business. Perbio Science supplies products, systems and services for the study and production of proteins and develops products in the Bioresearch, Cell Culture and Medical Device fields. The group has 1,353 employees and offices in Sweden, the USA and a number of other countries. Its head office is in Helsingborg, Sweden.

More information regarding Perbio Science can be found at www.perbio.com